| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в лютому 1998 (uk)
- article scientifique publié en 1998 (fr)
- im Februar 1998 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en febreru de 1998 (ast)
- artikull shkencor i botuar më 01 shkurt 1998 (sq)
- scientific article published on 01 February 1998 (en)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| rdfs:label
| - United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (en)
- United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (nl)
- United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (sq)
|
| skos:prefLabel
| - United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (en)
- United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (nl)
- United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (sq)
|
| name
| - United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (en)
- United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (nl)
- United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd (sq)
|
| title
| |
| title
| - United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.7326/0003-4819-128-3-199802010-00001
|
| is about
of | |
| is cites work
of | - The effect of different nutritional feeds on the postprandial glucose response in healthy volunteers and patients with type II diabetes
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
- Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group
- Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
- C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol
- Management of type 2 diabetes. Evolving strategies for treatment
- Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus
- Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment
- Glucose-induced insulin resistance of phosphatidylinositol 3'-OH kinase and AKT/PKB is mediated by the hexosamine biosynthesis pathway
- Assessment of pancreatic β-cell function: review of methods and clinical applications
- Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
- A risk-benefit assessment of metformin in type 2 diabetes mellitus
- Incretin therapy--present and future
- Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study
- Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus
- Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus
- The management of the obese diabetic patient
- Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
- Weight changes following the initiation of new anti-hyperglycaemic therapies.
- The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice
- Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes
- Noninsulin glucose-lowering agents for the treatment of patients on dialysis
- Biomarkers and functional foods for obesity and diabetes
- Afferent signals regulating food intake
- GPs' approach to insulin prescribing in older patients: a qualitative study
- Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study
- A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
- Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
- Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
- Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications have not helped?
- Personalizing guidelines for diabetes management: twilight or dawn of the expert?
- Orlistat: a review of its use in the management of patients with obesity
- The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
- Does hypoglycemia cause cardiovascular events?
- Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.
- Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
- Accuracy of continuous subcutaneous glucose monitoring with the GlucoDay in type 1 diabetic patients treated by subcutaneous insulin infusion during exercise of low versus high intensity.
- A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes
- Oral Insulin Delivery in a Physiologic Context: Review
- The Improving Primary Care of African Americans with Diabetes (IPCAAD) project: rationale and design
- Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation
- A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
- Glucose control guidelines: current concepts
- Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
- Breaking down barriers to initiating insulin: Insulin prescription pad.
- Characterization of the anti-diabetic and antioxidant effects of rehmannia glutinosa in streptozotocin-induced diabetic Wistar rats
- Antidiabetic Properties, Bioactive Constituents, and Other Therapeutic Effects of Scoparia dulcis
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)